PATENT CLAIM ANALYSIS

Application Number: 16039997
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "019300"]

Abstract:
A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.

Claim (Index 7):
The macromolecule according to  claim 1  wherein the dendrimer has 4 to 6 generations of building units.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 2.04545
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14124651', '15688780', '12161688', '13725844', '13570058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7980910372724692
- 35 USC 102 Novelty (BERT): 0.5628246254276356
- Combined Prediction Score: 0.7745643960879859
- Mean Citation Score: 342.6434700000001
- Max Citation Score: 434.95013
- Similarity Product: 377.35283974820567

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test